What drove today’s move in SAN.PA stock?

SAN.PA stock moved on a Q4 top-line beat, buyback news of **€1.20 billion**, and investor focus on pipeline funding. Intraday volume was **2,243,860** shares as markets priced in R&D and M&A priorities.

How does Sanofi’s dividend affect SAN.PA stock value?

Sanofi pays **€3.92** per share, a yield near **5.06%**, supporting income strategies. The dividend, combined with buybacks, underpins total return but growth depends on pipeline outcomes.

What are realistic price targets for SAN.PA stock?

We see three scenarios: conservative **€66.00** (-14.88%), base **€82.00** (+5.75%), and bullish **€105.00** (+35.42%). Targets reflect valuation, pipeline risk, and possible M&A.

Does Meyka AI expect SAN.PA stock to outperform?

Meyka AI's forecast model projects **yearly €78.94** (implied **+1.80%**). The model signals modest upside unless clinical readouts or acquisitions accelerate revenue growth.

EU Stocks

Q4 beat lifts Sanofi (SAN.PA EURONEXT): 29 Jan 2026 earnings focus on pipeline

ByHuzaifa Zahoor January 29, 2026January 29, 2026

Sanofi reported a quarterly beat that sent the SAN.PA stock down intraday despite positive fundamentals after the 29 Jan 2026 release. The Paris-listed company posted Q4 sales €11.30 billion (up 13% at constant currency) and signalled a €1.20 billion buyback to support shareholder returns. Investors are watching how growth from Dupixent and new launches will offset vaccine headwinds. Today’s intraday price is €77.54, with volume at 2,243,860 shares on EURONEXT, and the earnings call will frame the company’s R&D and M&A priorities for 2026.